Please use this identifier to cite or link to this item:
https://ninho.inca.gov.br/jspui/handle/123456789/13017| Title: | Gene therapy access: global challenges, opportunities, and views from Brazil, South Africa, and India |
| Authors: | Cornetta, Kenneth Bonamino, Martín Hernán Mahlangu, Johnny Mingozzi, Federico Rangarajan, Savita Rao, Jayandharan Giridhara Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA Molecular Carcinogenesis Program, Research Coordination, National Cancer Institute (INCA), Rio de Janeiro, Brazil; Vice-Presidency of Research and Biological Collections (VPPCB), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Brazil. Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Spark Therapeutics, Philadelphia, PA 19104, USA. Faculty of Medicine University of Southampton, UK & KJ Somaiya Super Speciality Hospital and Research Centre, Mumbai, India. Department of Biological Sciences and Bioengineering, Indian Institute of Technology Kanpur, Kapur, UP, India. |
| Keywords: | Terapia Baseada em Transplante de Células e Tecidos Cell-and Tissue-Based Therapy Tratamiento Basado en Trasplante de Células y Tejidos Terapia Genética Genetic Therapy |
| Issue Date: | 2022 |
| Publisher: | Molecular Therapy |
| Citation: | CORNETTA, Kenneth; BONAMINO, Martín; MAHLANGU, Johnny; MINGOZZI, Federico; RANGARAJAN, Savita; RAO, Jayandharan. Gene therapy access: global challenges, opportunities, and views from brazil, south africa, and india. Molecular Therapy, [S.L.], v. 30, n. 6, p. 2122-2129, jun. 2022. DOI: http://dx.doi.org/10.1016/j.ymthe.2022.04.002. |
| Series/Report no.: | v. 30;n. 6 |
| Abstract: | Gene and cell therapies for a variety of life-limiting illnesses are under investigation, and a small number of commercial products have successfully obtained regulatory approval. The cost of treatment is high, and clinical studies evaluating safety and efficacy are performed predominately in high-income countries. We reviewed the current status of gene and cell therapies in low- and middle-income countries and highlighted the need and current barriers to access. The state of product development in Brazil, South Africa, and India is discussed, including lessons learned from American Society of Gene and Cell Therapy (ASGCT)-sponsored virtual symposia in each of these countries. |
| Description: | v. 30, n. 6, p. 2122-2129, jun. 2022 |
| URI: | https://ninho.inca.gov.br/jspui/handle/123456789/13017 |
| ISSN: | 1525-0016 |
| Appears in Collections: | Artigo de Periódicos da Pesquisa Clínica |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Gene therapy access - Global challenges, opportunities, and views from Brazil, South Africa, and India - 2022.pdf | 391.62 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.